**Information regarding COVID testing**

All patients with symptoms that could be associated with COVID infection are covered by insurance or government programs at 100% at this time.

Patients may join the virtual waiting room by texting *Masonboro* to 910-363-2836 or phoning Masonboro Urgent Care at 910-794-4947.

**Indications for COVID 19 Testing (paid by insurance or government plan) per 9/16/2020 CDC guidelines:**

1.) Symptoms of COVID 19: fever or chills, cough, shortness of breath, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea, other symptoms.
    a. CDC Recommendation: Must isolate until negative test result is received and is without symptoms for 24 hours without fever reducing medication.
    b. Positive results must isolate for 10 days, but cannot leave isolation until 24 hours after symptoms are improving and no fever without fever reducing medication, whichever is longer.
2.) Close Contact with someone with positive COVID
    a. Close contact is defined as being within 6 feet for more than 15 minutes with neither party wearing a mask
    b. CDC Recommendations: Negative result must isolate for 14 days from date of contact.
    c. Positive results isolate 10 days from the date of positive test sample.
3.) Present at a high probability of transmission event: a large gathering of 10 or more people without universal masking or physical distancing.
    a. CDC Recommendation; Must isolate until negative test result is received
4.) Work in or live in or receive care at a Nursing Home.
    a. Recommendation: Not necessary to isolate until negative test results are received.
5.) Critical infrastructure worker, healthcare worker or first responder.
    a. CDC Recommendations: Not necessary to isolate until negative test results are received.)

**Due to lack of supplies we are doing Rapid testing for Asymptomatic, Unexposed testing only.**

**General Information:**
**Not Medically Indicated for COVID 19 Testing (Not billed to insurance or gov't program): This would be paid for privately:**

1.) No COVID symptoms or close contact.
2.) Pre-Travel, Employer mandated, school mandated, etc.
3.) Geographically mandated by government Post Travel.

**Not medically indicated cost:**

**Rapid Antigen: 150.00**
**Rapid RNA (Abbott ID Now): 175.00**
**Sent out LabCorp RNA: 165.00**

**COVID Antigen testing:** COVID Antigen testing was designed to screen for the SARS COV 2 virus in symptomatic patients within 5 days of onset of symptoms. This test detects protein of the virus that causes COVID 19.
Disadvantage is limited supply. It will diagnose a positive case approximately 84% of the time

**Asymptomatic screening, Unexposed:**
Antigen testing is used but not designed to be used as a screening tool.

If an asymptomatic patient agrees to the waiver, we can test them using the rapid antigen test. This is a Private Pay option only. We will not bill this to their insurance or any government program.

Antigen testing detects positive COVID 84% of the time. If the result is positive, the test's accuracy is dependent upon the rate of disease in the community and therefore positive tests are confirmed by RNA test sent to LabCorp.

The patient with a positive result will be assessed by a provider and insurance will be billed.

**Rapid Abbott ID Now RNA test:**
This is a hybrid RNA test that is designated for both diagnosis and screening.
The advantage of this test is that the results are available within 15 minutes.
Disadvantage is limited supply. It will diagnose a positive case approximately 90% of the time.

**Send out LabCorp RNA test:**
This test usually takes 2-5 days for the result to return.
Return time is dependent upon lab volume and therefore cannot be guaranteed.
This test will diagnose a positive case approximately 94% of the time.

**All of the above tests are:**

## FDA Status: ▪ U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA)

This test has not been FDA cleared or approved.
This test has been authorized by FDA under an Emergency Use Authorization (EUA). These tests are only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C.360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

**Updated 10/15/2020 PRM**